BioCentury | Aug 14, 2020
Deals

Data Bytes: Bayer building women’s health portfolio

Bayer’s takeout of KaNDy Therapeutics Ltd. this week is the pharma’s third deal in women’s health this year. In the past decade, the company has closed at least seven R&D, M&A or in-licensing agreements in the...
BioCentury | Aug 14, 2020
Finance

Non-European venture investment in European biotech is on the rise

European biotechs are seeing more participation by non-European investors in venture rounds than they’ve seen in the last three years, and the median size of the financings has outstripped solely domestic rounds. BioCentury analyzed 133 European...
BioCentury | Aug 13, 2020
Emerging Company Profile

RA-incubated Aerovate to deploy $72.6M series A for inhaled imatinib for PAH

Aerovate emerged from RA Capital’s incubator last week with a $72.6 million series A round to support clinical testing of an inhaled dry powder formulation of imatinib for PAH that’s designed to avoid the systemic...
BioCentury | Aug 13, 2020
Management Tracks

NHC’s Boutin to head patient advocacy at Novartis; plus changes at Moderna, PIC, Atea, Terns, NBE and Omega

National Health Council CEO Marc Boutin has joined Novartis AG (NYSE:NVS; SIX:NOVN) as global head of patient engagement and advocacy. The NHC is  an umbrella group comprising more than 140 healthcare organizations and businesses that...
BioCentury | Aug 12, 2020
Deals

Single-asset KaNDy finds $425M exit as Bayer continues to build women’s health portfolio

Bayer’s $425 million takeout of menopause play KaNDy sends a signal to investors that women’s health can deliver a return. Private companies working in the space have long struggled to raise venture money. “Women’s health,...
BioCentury | Aug 11, 2020
Finance

Aug. 10 Quick Takes: Megarounds for Lepu, Dyne; plus CureVac’s IPO plans, top marks for Chinese biotech trio and more

Riverhead, Ping An lead Lepu’s megaround Lepu Biotechnology Co. Ltd. raised RMB1.3 billion ($185.3 million) in a series B round jointly led by Riverhead Capital and Ping An Capital, with participation by Haitong Innovation Capital Management,...
BioCentury | Aug 11, 2020
Emerging Company Profile

Through LianBio, Perceptive forms bridge for Western pipeline into Asia

Led by Bing Li and Debra Yu, Perceptive’s LianBio has launched with the goal of speeding the entrance of new medicines into Asian markets, leading with a registration-ready cardiomyopathy candidate from MyoKardia and a Phase...
BioCentury | Aug 8, 2020
Translation in Brief

Cocrystal’s COVID-19 antivirals; plus a portable breast cancer diagnostic, Tarveda mini-drug conjugate for solid tumors, and more

Broad-spectrum coronavirus protease inhibitors A Wichita State University, University of Iowa and Kansas State University team reported in a Science Translational Medicine article the generation of a series of inhibitors of the protease 3CLpro from...
BioCentury | Aug 8, 2020
Management Tracks

PacBio shifts executive team; plus changes at CMAB, Valo, Alentis, Amwell and more

Pacific Biosciences of California Inc. (NASDAQ:PACB) announced a series of management changes Friday. Chairman Christian Henry will become president and CEO, effective Sept. 14. John Milligan, a member of the sequencing company’s board, will succeed...
BioCentury | Aug 8, 2020
Product Development

Novavax secures multicountry access to COVID-19 vaccine

Building on its commitment to make its COVID-19 vaccine globally accessible, Novavax closed two partnerships this week to supply Japan, India and lower income countries with doses of NVX-CoV2373. The biotech plans to start a...
Items per page:
1 - 10 of 19438